ABL1 and acute lymphoblastic leukemia: The presence of pretreatment, clinically relevant subclonal mutations could have important implications for personalized therapy decisions in Ph + ALL, including the early incorporation of broad-spectrum BCR-ABL1 TKIs that target T315I or other ABL1 resistance mutations for select patients where these are identified.